CCRM
Michael Israels is a seasoned finance professional with extensive experience in leadership roles within the regenerative medicine and asset management sectors. Currently serving as Chief Financial Officer at the Centre for Commercialization of Regenerative Medicine (CCRM) since November 2013, Michael also holds directorships at OmniaBio, CCRM Australia, and the Canadian Advanced Therapies Training Institute (CATTI) Inc. Prior experience includes serving as CFO at ExCellThera Inc. and leading asset management advisory services at Ernst & Young. Michael's educational background includes an Honors degree in Business Administration from Ivey Business School at Western University, along with professional designations as a Chartered Professional Accountant and Chartered Business Valuator.
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.